Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.
Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:
(12) Patent: | (11) CA 2200541 |
---|---|
(54) English Title: | LHRH-ANTAGONISTS IN THE TREATMENT OF FERTILITY DISORDERS |
(54) French Title: | UTILISATION D'ANTAGONISTES DE LA LH-RH DANS LE TRAITEMENT DES TROUBLES DE L'INFERTILITE |
Status: | Term Expired - Post Grant Beyond Limit |
(51) International Patent Classification (IPC): |
|
---|---|
(72) Inventors : |
|
(73) Owners : |
|
(71) Applicants : |
|
(74) Agent: | SMART & BIGGAR LP |
(74) Associate agent: | |
(45) Issued: | 2013-02-19 |
(22) Filed Date: | 1997-03-20 |
(41) Open to Public Inspection: | 1998-07-22 |
Examination requested: | 2002-02-05 |
Availability of licence: | N/A |
Dedicated to the Public: | N/A |
(25) Language of filing: | English |
Patent Cooperation Treaty (PCT): | No |
---|
(30) Application Priority Data: | ||||||
---|---|---|---|---|---|---|
|
A method of treating infertility disorders by 1) administering an
LH-RH antagonist, preferably Cetrorelix, in amounts to selectively
suppress endogenous LH but not FSH secretion and 2) inducing follicle
growth by administration of exogenous gonadotropin. The selective
suppression OF LH allows FSH secretion to be at natural level S thereby not
affecting individual estrogen development. The LH-RH antagonist can be
given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg,
preferably 2 mg - 6 mg. In multiple dosing posology, LH-RH antagonist
can be administered subcutaneously in an amount in the range of 0.1 to 0.5
mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle
day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between
day 9 and 20 of the menstruation cycle by administering rec. LH, native
LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or
LH-RH agonist can be given to avoid hyperstimulation syndrome and
native LH-RH or a LH-RH agonist can be administered to avoid luteal
phase stimulation by neutralizing the negative effects of HCG.
Méthode de traitement des troubles de l'infertilité comportant les étapes suivantes : 1) administration d'un antagoniste de la LH-RH, de préférence Cetrorelix, en quantité suffisante pour supprimer la LH endogène, mais non la sécrétion de FSH, et 2) induction d'une croissance folliculaire par administration de gonadotrophine exogène. La suppression sélective de la LH permet à la sécrétion de la FSH de se maintenir au niveau naturel S et ne perturbe donc pas le développement individuel des oestrogènes. L'antagoniste de la LH-RH peut être administré par voie sous-cutanée en dose unique ou double de l'ordre de 1 à 10 mg, de préférence 2 à 6 mg. Dans une posologie à doses multiples, l'antagoniste de la LH-RH peut être administré par voie sous-cutanée à raison de 0,1 à 0.5 mg par jour. L'administration commence entre le 1er et le 10e jour du cycle, de préférence entre le 4e et le 8e, et l'ovulation peut être induite entre le 9e et le 20e jour par administration de LH rec., de LH-RH native, d'agonistes de la LH-RH ou de HCG. On peut aussi administrer de la LH rec., de la LH-RH native ou un agoniste de la LH-RH pour éviter de stimuler la phase lutéale en neutralisant les effets négatifs de la HCG.
Note: Claims are shown in the official language in which they were submitted.
Note: Descriptions are shown in the official language in which they were submitted.
Sorry, the representative drawing for patent document number 2200541 was not found.
2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.
Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.
For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee and Payment History should be consulted.
Description | Date |
---|---|
Inactive: Expired (new Act pat) | 2017-03-20 |
Grant by Issuance | 2013-02-19 |
Inactive: Cover page published | 2013-02-18 |
Inactive: Final fee received | 2012-12-06 |
Pre-grant | 2012-12-06 |
Letter Sent | 2012-10-29 |
Letter Sent | 2012-10-29 |
Inactive: Single transfer | 2012-10-04 |
Notice of Allowance is Issued | 2012-06-22 |
Letter Sent | 2012-06-22 |
Notice of Allowance is Issued | 2012-06-22 |
Inactive: Approved for allowance (AFA) | 2012-06-18 |
Amendment Received - Voluntary Amendment | 2012-05-17 |
Inactive: S.30(2) Rules - Examiner requisition | 2012-01-06 |
Amendment Received - Voluntary Amendment | 2011-10-19 |
Inactive: S.30(2) Rules - Examiner requisition | 2011-05-09 |
Letter Sent | 2010-06-18 |
Amendment Received - Voluntary Amendment | 2010-06-03 |
Reinstatement Requirements Deemed Compliant for All Abandonment Reasons | 2010-06-03 |
Reinstatement Request Received | 2010-06-03 |
Inactive: Abandoned - No reply to s.30(2) Rules requisition | 2009-07-14 |
Inactive: S.30(2) Rules - Examiner requisition | 2009-01-14 |
Letter Sent | 2006-05-24 |
Inactive: Single transfer | 2006-04-18 |
Amendment Received - Voluntary Amendment | 2004-08-25 |
Inactive: S.30(2) Rules - Examiner requisition | 2004-02-25 |
Inactive: S.29 Rules - Examiner requisition | 2004-02-25 |
Amendment Received - Voluntary Amendment | 2002-11-08 |
Amendment Received - Voluntary Amendment | 2002-03-01 |
Letter Sent | 2002-02-27 |
All Requirements for Examination Determined Compliant | 2002-02-05 |
Request for Examination Requirements Determined Compliant | 2002-02-05 |
Request for Examination Received | 2002-02-05 |
Application Published (Open to Public Inspection) | 1998-07-22 |
Inactive: Office letter | 1997-12-09 |
Request for Priority Received | 1997-11-28 |
Letter Sent | 1997-09-25 |
Inactive: IPC assigned | 1997-08-01 |
Inactive: IPC assigned | 1997-08-01 |
Inactive: First IPC assigned | 1997-08-01 |
Inactive: Single transfer | 1997-07-17 |
Abandonment Date | Reason | Reinstatement Date |
---|---|---|
2010-06-03 |
The last payment was received on 2012-02-17
Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following
Please refer to the CIPO Patent Fees web page to see all current fee amounts.
Note: Records showing the ownership history in alphabetical order.
Current Owners on Record |
---|
ZENTARIS IVF GMBH |
Past Owners on Record |
---|
JURGEN ENGEL |
KLAUS DIEDRICH |
PAUL DEVROEY |
PHILIPPE BOUCHARD |
RENE FRYDMAN |